Tnf Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Chelsea Sierra Voss acquired 1,753 shares of Q/C Technologies, Inc. (QCLS) common stock at a price of $3.15 per share.
Director Stephen Friscia was granted 50,000 employee stock options in Q/C Technologies, Inc. with an exercise price of $5.00.
Director Chelsea Voss was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Chief Medical Officer Mitchell Glass was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Director Billy Joe White was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Director Bruce Bernstein was granted 50,000 employee stock options in Q/C Technologies, Inc. on April 13, 2026.
Executive Chairman Joshua Silverman acquired 162,162 restricted stock units and 100,000 stock options in Q/C Technologies, Inc.
Chelsea Sierra Voss, a Director at Q/C Technologies, Inc., was granted 237,500 Restricted Stock Units and 212,500 stock options, vesting quarterly.
PharmaCyte Biotech, a 10% owner of Q/C Technologies (QCLS), reported acquiring 889,865 Series H convertible preferred shares and 889,865 warrants, now convertible/exercisable following shareholder approval on November 14, 2025.
Q/C Technologies, Inc. Director and Chief Medical Officer Mitchell Glass was granted 11,420 Restricted Stock Units, which vested immediately upon stockholder approval of a plan amendment.
Q/C Technologies, Inc. director Billy Joe White was granted 22,839 shares of common stock following stockholder approval of an equity incentive plan amendment.
Q/C Technologies, Inc. Executive Chairman Joshua Silverman received a grant of 91,356 restricted stock units, which vested immediately.
Q/C Technologies, Inc. Director Stephen Friscia reported the acquisition of 22,839 shares of common stock through a Restricted Stock Unit grant following stockholder approval.
Q/C Technologies, Inc. Director Bruce Bernstein acquired 25,000 shares of common stock through a Restricted Stock Unit grant that vested immediately upon stockholder approval.
Q/C Technologies' Vice President of Finance, Gary M. Rauch, acquired 11,420 shares of common stock through a Restricted Stock Unit grant.
Q/C Technologies, Inc. Executive Chairman Joshua Silverman was granted 8,644 Restricted Stock Units, which vested immediately on October 3, 2025.
Q/C Technologies Director Stephen Friscia acquired 2,161 shares of common stock through an immediately vested Restricted Stock Unit grant.
Mitchell Glass, Director and Chief Medical Officer of Q/C Technologies, Inc., acquired 1,080 shares of common stock through an immediately vested Restricted Stock Unit grant.
Q/C Technologies Director Billy Joe White was granted 2,161 Restricted Stock Units, which vested immediately on October 3, 2025.
Q/C Technologies' Vice President of Finance, Gary M. Rauch, was granted 1,080 shares of common stock through immediately vested Restricted Stock Units.
Gary Rauch, Vice President of Finance at TNF Pharmaceuticals, acquired 75,000 employee stock options on April 17, 2025, at an exercise price of $0.1832.
Ian Rhodes, Interim CFO of TNF Pharmaceuticals, acquired 25,000 employee stock options on April 17, 2025.
Mitchell Glass, President and CMO of TNF Pharmaceuticals, acquired 125,000 employee stock options on April 17, 2025.